Cannabidiol - MMJ PhytoTech

Drug Profile

Cannabidiol - MMJ PhytoTech

Alternative Names: PTL101

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MMJ PhytoTech
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epilepsy

Most Recent Events

  • 01 Feb 2018 Safety and efficacy data from a phase II trial in Epilepsy released by Harvest One Cannabis
  • 26 Dec 2016 PhytoTech Therapeutics plans a phase II trial for Epilepsy in Israel (NCT02987114)
  • 31 Oct 2016 PhytoTech Therapeutics in-licenses Gelpell® product technology from Gelpell AG (MMJ PhytoTech's Annual report, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top